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Tumor-stroma interactionsThe TGFβ signaling pathway has pleiotropic functions regulating cell growth, differentiation, apoptosis, motility
and invasion, extracellular matrix production, angiogenesis, and immune response. TGFβ signaling deregulation
is frequent in tumors and has crucial roles in tumor initiation, development and metastasis. TGFβ signaling inhi-
bition is an emerging strategy for cancer therapy. The role of the TGFβ pathway as a tumor-promoter or suppres-
sor at the cancer cell level is still a matter of debate, due to its differential effects at the early and late stages of
carcinogenesis. In contrast, at themicroenvironment level, the TGFβ pathway contributes to generate a favorable
microenvironment for tumor growth and metastasis throughout all the steps of carcinogenesis. Then, targeting
the TGFβ pathway in cancer may be considered primarily as a microenvironment-targeted strategy. In this
review, we focus on the TGFβ pathway as a target for cancer therapy. In the ﬁrst part, we provide a comprehen-
sive overview of the roles played by this pathway and its deregulation in cancer, at the cancer cell and microen-
vironment levels. We go on to describe the preclinical and clinical results of pharmacological strategies to target
the TGFβ pathway,with a highlight on the effects on tumormicroenvironment.We then explore the perspectives
to optimize TGFβ inhibition therapy in different tumor settings.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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The transforming growth factor-β (TGFβ) superfamily consists of
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Fig. 1. Overview of the TGFβ family pathways. All of the ligands of the TGFβ family are initially synthesized and secreted as latent precursors that need to be proteolytically processed by
extra-cellular pro-protein convertases to produce biologically active dimeric ligands. The signal transduction mechanism for all of them is similar. It requires ligand binding to one of the
ﬁve distinct members of constitutively activatedmembranous type II serine/threonine kinase receptors, and subsequent recruitment and transphosphorylation of one of the seven type I
serine/threonine kinase receptors, also known as activin receptor-like kinases (ALK1-7) (Wakeﬁeld & Hill, 2013). For some ligands, additional co-receptors are required for optimal ligand
binding and activation of the type I-type II receptor heterodimer. After phosphorylation, the type I receptor kinase domain becomes activated and can then activate the canonical (SMAD-
dependent) pathway through phosphorylation of the receptor-regulated SMAD proteins (R-SMAD). It is classically admitted that TGFβs, activins, and NODAL signal through SMAD2 and
SMAD3, and BMPs and GDFs through SMAD1, SMAD5, and SMAD8, but TGFβs can also induce phosphorylation of SMAD1 and SMAD5 (Wakeﬁeld & Hill, 2013). The R-SMADs form
heteromeric complexes with SMAD4 in early endosomes, through a clathrin-dependent internalization pathway that requires accessory proteins such as SARA (Bierie & Moses, 2006;
Ikushima &Miyazono, 2010). These complexes then translocate and accumulate into the nucleus and bind to site-speciﬁc recognition sequenceswithin the promoter regions of hundreds
of target genes to directly regulate their transcription, both positively and negatively. Various other DNA binding co-factors such as p300, CBP, and FOXH1 can interact with SMAD com-
plexes to amplify SMAD-dependent gene transcription. The TGFβ superfamily pathway activities are subject to numerous levels of regulation: interaction of the ligands with extracellular
antagonists that prevent their binding to receptors; modulation of R-SMAD stability through phosphorylation byMAPKs, glycogen synthase kinase 3β (GSK3β) and cyclin-dependent ki-
nases (CDKs); Smurf (SMAD-ubiquitination-regulatory factor)-dependent degradation; or expression of inhibitory SMADproteins (I-SMAD), SMAD6 and SMAD7 (Wakeﬁeld &Hill, 2013).
In the non-canonical pathway, TGFβ signaling activates SMAD-independent pathways such as PI3K/AKT, MAPK pathways (ERK, JNK, and p38 MAPK), c-Src, NF-κB, FAK, Abl, or small
GTPases such as RhoA, Rac1 and Cdc42. Moreover, transversal signaling, especially at the SMAD level, allows TGFβ pathway activation to integrate signals from integrins, Wnt/β-catenin,
Notch, Hedgehog, TNF-α, or EGF-dependent pathways (Watabe & Miyazono, 2009; Sakaki-Yumoto et al., 2013).
23C. Neuzillet et al. / Pharmacology & Therapeutics 147 (2015) 22–31their structure, synthesis, signal transduction mechanisms and regu-
lation [Fig. 1] (Bierie & Moses, 2006; Watabe & Miyazono, 2009;
Ikushima & Miyazono, 2010; Sakaki-Yumoto et al., 2013; Wakeﬁeld
& Hill, 2013).
The TGFβ superfamily signaling pathways have pleiotropic functions
regulating cell growth, differentiation, apoptosis, motility and invasion,
extracellular matrix (ECM) production, angiogenesis, and immune re-
sponse. They play essential roles in early embryonic development and
in regulating tissue homeostasis in adults (Wakeﬁeld & Hill, 2013).
Deregulated signaling by many of these members has crucial roles in
both the development of tumors and metastasis. Their inﬂuence ex-
tends beyond the cancer cells themselves, to the tumor microenviron-
ment and the whole organism. Furthermore, these signaling pathways
are emerging therapeutic targets. Among the TGFβ-superfamily mem-
bers, the TGFβs themselves have been the most studied and inhibitors
of this pathway are the most advanced in their clinical development.The role of the TGFβ pathway as a tumor-promoter or suppressor at
the cancer cell level is still a matter of debate, due to its differential ef-
fects at the early and late stages of carcinogenesis. In contrast, at the
microenvironment level, the TGFβ pathway contributes to generate a
favorablemicroenvironment for tumor growth andmetastasis through-
out all the steps of carcinogenesis. Then, targeting the TGFβ pathway for
cancer therapy may be considered primarily as a microenvironment-
targeted strategy.
In this review, we focus on the TGFβ pathway as a target for cancer
therapy. In the ﬁrst part, we provide a comprehensive overview of the
roles played by this pathway and its deregulation in cancer, at the can-
cer cell and microenvironment levels. We go on to describe the preclin-
ical and clinical results of pharmacological strategies to target the TGFβ
pathway, with a highlight on the effects on tumor microenvironment.
We then explore the perspectives to optimize TGFβ inhibition therapy
in different tumor settings.
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2.1. At the cancer cell level: dual
tumor-promoter and suppressor role of TGFβ signaling
Hijacking crucial biological functions by deregulating the TGFβ
signaling pathway by cancer cells has recently emerged as a leading
area of preclinical and clinical cancer research. TGFβ expression has
been studied in a large panel of cancer types, including prostate, breast,
lung, colorectal, pancreatic, liver, skin cancers, and gliomas (Padua &
Massague, 2009). In early-stage tumors, levels of TGFβ are positively as-
sociated with a favorable prognosis, while in advanced tumors, they are
positively associated with tumor aggressiveness and poor prognosis
(Padua &Massague, 2009). Through these observations, it has emerged
that TGFβ pathway has both anti- and pro-tumoral activities (Inman,
2011; Principe et al., 2014). In early-stage tumors, the TGFβ pathway
promotes cell cycle arrest and apoptosis (Jakowlew, 2006; Tian et al.,
2011; Drabsch & ten Dijke, 2012). In contrast, at advanced stages, by
promoting cancer cell motility, invasion, epithelial-to-mesenchymal
transition (EMT), and cell stemness, the TGFβ pathway promotes
tumor progression and metastasis (Jakowlew, 2006; Tian et al., 2011;
Drabsch & ten Dijke, 2012). This functional switch is known as the
ﬁrst “TGFβ paradox” (Wendt et al., 2012).
The current paradigm for the role of TGFβ in carcinogenesis at the
cancer cell level is that accumulation of genetic alterations in the TGFβ
pathway drives the pathway’s evolution from tumor-suppressive to
tumor-promoting activities (Jakowlew, 2006; Neuzillet et al., 2014). In-
deed, tumor progression requires shutting down the tumor-suppressive
effects of the TGFβ signaling, which can be reached by either of two gen-
eralmechanisms. The ﬁrst one consists in “decapitation” of the pathway
by inactivation, either through mutation or through allelic loss of het-
erozygosity (LOH), of its core components: the receptors (TGFBR2,
TGFBR1) or the SMAD transcription factors (SMAD2, SMAD4/DPC4)
(Padua&Massague, 2009). For example, TGFBR2-inactivatingmutations
are frequently found in cancers associatedwithmicrosatellite instability
(MSI), which arises from defects in themismatch repair system, and are
associated with high CpG island methylator phenotype (Markowitz
et al., 1995; Ogino et al., 2007; Shima et al., 2011). The TGFBR2 gene con-
tains a 10-base pair poly-adenine repeat,which is exposed to replication
errors leading to gene inactivation speciﬁcally in MSI+ cancers, includ-
ing gastric, colorectal, biliary and lung adenocarcinomas. Alternatively,
SMAD4/DPC4 is found inactivated in about 50% of pancreatic ductal ad-
enocarcinoma (PDAC), either by 18q LOH or mutation, and in colon
and oesophagus cancers, (Padua &Massague, 2009). These genetic inac-
tivations of core components of the TGFβ pathway result in elimination
of most or all of TGFβ responses including tumor-suppressive activities,
and cooperate with other genetic alterations to promote tumor initia-
tion and malignant progression. Mice models harboring oncogenic mu-
tation (APC for colon cancer, KRAS for PDAC) combined with SMAD4 or
TGFBR2 inactivation display accelerated cancer development with
more aggressive behaviour compared with mice without combined
TGFβ signaling alteration (Datto & Wang, 2000; Morris et al., 2010). In
contrast, breast, prostate cancers, melanomas, and gliomas, frequently
retain functional TGFβ signaling but selectively “amputate” the tumor
suppressor arm downstream these core components, for example
through P15INK4B deletion or C/EBPβ inhibition (Padua & Massague,
2009). These tumors can beneﬁt from the remaining TGFβ activities
promoting tumor progression and metastasis, such as invasion and
EMT. Similarly, in HCC, anti-proliferative effects of TGFβ are bypassed
via mitogenic signals or impaired sensitivity to anti-growth signals
(Neuzillet et al., 2014). Coulouarn et al. (Coulouarn et al., 2008) de-
scribed the switch from a tumor-suppressive “early TGFβ signature”,
with low endogenous levels of TGFβ and SMAD7 and strong transcrip-
tional SMAD3 activity, and which was correlated with better outcome
in HCC patients, to a “late TGFβ signature”, with high amounts of TGFβ
and SMAD7 and reduced SMAD3 signaling, associated with invasivephenotype and increased tumor recurrence. The early TGFβ signature is
also characterized by expression of the DNA damage gene family
Gadd45, which is involved in cell cycle arrest and apoptosis (Coulouarn
et al., 2008; Dooley & ten Dijke, 2012). Given this strong induction of
anti-tumorigenic genes, tumor promoting activity of TGFβ requires a cel-
lular context with imbalanced sensitivity towards pro- and anti-growth
signals (Neuzillet et al., 2014). For example, p16INK4 gene alterations are
present in up to 90% of HCCs and favour insensitivity to anti-growth sig-
nals by relieving cyclin D/CDK4,6 complex inhibition and lowering p53
activation (Neuzillet et al., 2013). Once the tumor-suppressive effects of
the TGFβ signaling shut down, it can exert its pro-tumoral and pro-
metastatic activities in late steps of carcinogenesis.
To summarize, the TGFβ pathway has dual anti- and pro-tumoral
roles at the cancer cell level, depending on tumor stage and genetic al-
teration background, with mechanistic differences between cancer
models. This complexity, combined with intratumor genetic heteroge-
neity, makes the resulting effects of TGFβ inhibition on cancer cell com-
partment difﬁcultly predictable. Moreover, the fact that TGFβ induces
pro-tumoral effects although its signaling is shut down in cancer cells
represents a second “paradox” that leads to shift attention to themicro-
environment surrounding cancer cells.
2.2. At the microenvironment level: a key thread of pro-tumoral activities
The TGFβ pathway exerts most of its pro-tumoral effects bymediat-
ing tumor-stroma interactions and remodeling tumor microenviron-
ment (Neuzillet et al., 2014). The stroma is a complex structure
composed of ECM proteins (mainly, type I collagen) and various cell
types including mesenchymal cells (cancer-associated ﬁbroblasts
[CAF]), endothelial cells and pericytes, nerve cells, immune cells, and
bone marrow-derived stem cells. These cell types express TGFβ recep-
tors, and the TGFβ pathway can thus impacts microenvironment ﬁbro-
sis, angiogenesis, and immune cell inﬁltration (Neuzillet et al., 2014).
The TGFβ pathway activation contributes both to the creation, from a
non-tumoral environment, and to the maintenance of a favorable
tumoral microenvironment.
2.2.1. Effect on tumor initiation
SMAD4/DPC4 germline inactivating mutation is genetically responsi-
ble for familial juvenile polyposis, an autosomal dominant inherited con-
dition characterized by the development of multiple hamartomatous
tumors in the gastrointestinal tract and predisposition to cancer. Animal
models with a loss of SMAD function have provided insight into the role
of SMADs in a variety of physiologic systems and tumors (Takaku et al.,
1998; Datto & Wang, 2000). Using genetically engineered mice models
of familial juvenile polyposis inwhich the SMAD4 gene is either speciﬁcal-
ly deleted in T-cells or broadly within epithelia including the intestinal
mucosa, Kim et al. (Kim et al., 2006) showed that selective disruption of
SMAD4 within the T-lineage in mice is sufﬁcient to induce the formation
of hamartomatous lesions and cancer within the gastrointestinal mucosa,
contrary to epithelial-speciﬁc deletion of the SMAD4 gene. Then, SMAD4-
dependent signaling in T-lymphocytes is required to maintain immune
homeostasis and cancer suppression within the gastrointestinal mucosa,
and alterations of the TGFβ signaling in themicroenvironment contribute
to create a favorable context for cancer development.
About 15% of human cancers emerge on underlying chronic inﬂam-
matory diseases, e.g. colorectal cancer on colitis/Crohn's disease, gastric
cancer on chronic gastritis, HCC on liver chronic hepatitis/cirrhosis,
PDAC on chronic pancreatitis (Coussens & Werb, 2002). As described
in the physiological response in injured organs, TGFβ1 is produced in
response to pro-inﬂammatory cytokines (e.g., tumor necrosis factor
[TNFα], interleukin [IL]-1) in tumors, particularly by stromal cells, as
an attempt to control the inﬂammatory reaction (Lopez-Novoa &
Nieto, 2009). The activation of the TGFβ pathway results in increased
production and reduced degradation of ECM components, in particular
type I collagen, as well as mesenchymal cell proliferation and
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capabilities (Lopez-Novoa & Nieto, 2009; Pohlers et al., 2009; Van De
Water et al., 2013). TGFβ stimulates reactive oxygen species (ROS)
production by various mechanisms (including activation of NADPH
oxidases [NOX] family members) that, in turn, engage downstream
signaling pathways (e.g., SMADs, EGFR, Src and MAPK family) resulting
in expression of a subset of pro-ﬁbrotic genes (e.g., PAI-1, connective
tissue growth factor [CTGF], TGFβ1, angiotensiogen) (Samarakoon
et al., 2013). TGFβ overproduction, as a driver of the ﬁbrotic process of
chronic phases of inﬂammatory diseases, precedes tumor formation and
prepares a favorable microenvironment for cancer cells (Jakowlew,
2006; Lopez-Novoa & Nieto, 2009).
2.2.2. Effect on tumor maintenance and progression
Some established tumors are characterized by a dense ﬁbrotic
stroma (e.g., PDAC). CAFs and stellate cells are responsible for excess
ECM production and are engaged through signaling pathways in an
“unholy alliance” with cancer cells (Vonlaufen et al., 2008; Coulouarn
& Clement, 2014). TGFβ1 is a key mediator of this dialogue between
CAFs or stellate cells and cancer cells. Cancer cells release mitogenic
and ﬁbrogenic stimulants (including TGFβ, PDGF, and sonic hedgehog),
which activate surrounding CAFs and stellate cells. Activated CAFs and
stellate cells in turn secrete various factors (including EGF, IGF-1,
PDGF, FGF,MMP, and type I collagen) that promote tumor growth, inva-
sion, metastasis, and resistance to chemotherapy (Duner et al., 2010).
They also contribute to create a hypoxic microenvironment exerting a
selection pressure toward a more invasive cancer cell phenotype
(Duner et al., 2010). Overall, the stroma may act either as a barrier or
a facilitator to metastatic dissemination depending on collagen I struc-
ture (Levental et al., 2009).
The TGFβ pathway also plays a pro-tumoral role by promoting
angiogenesis (tenDijke & Arthur, 2007; Neuzillet et al., 2014). It cooper-
ates in an autocrine/paracrine fashionwith other signaling cascades, in-
cluding vascular endothelial growth factor (VEGF), basic ﬁbroblast
growth factor (bFGF), platelet-derived growth factor (PDGF), CTGF,
angiopoietin, andNotch, to regulate angiogenesis through direct or indi-
rect effects on quiescence, migration, and proliferation of endothelial
cells (Sakurai & Kudo, 2011). TGFβ has both pro-angiogenic and anti-
angiogenic properties, depending on its expression level. Low levels of
TGFβ contribute to angiogenesis indirectly by upregulating expression
and activity of angiogenic factors (VEGF, bFGF, CTGF) and proteases,
while high levels of TGFβ stimulate basement membrane reformation,
recruit smooth muscle cells, increase differentiation, and inhibit
endothelial cell growth (Sanchez-Elsner et al., 2001; Sakurai &
Kudo, 2011). TGFβ plays a crucial role in angiogenesis regulation in
hypervascularized tumors such as HCCs or gliomas (Ito et al., 1995;
Roy et al., 2014).
Many lines of preclinical evidence suggest that TGFβ plays a cen-
tral role in immune regulation (Wojtowicz-Praga, 2003; Teicher,
2007; Yang, 2010). The immune system is responsible for the early
detection and destruction of cancer cells. These latters can escape
immune surveillance either by becoming immunologically invisible
(i.e., cancer cell “hiding”) or by secreting cytokines that “blind” the
immune system to the presence of abnormal antigens at the cancer
cell surface. TGFβ1 is the most potent immunosuppressor and plays
a crucial role in this process, along with IL-10. Tumor-associated
TGFβ1 downregulates the host immune response via several mecha-
nisms: it (1) drives the T-helper (Th)1/Th2 balance toward the Th2
immune phenotype (i.e., humoral immunity, without cytotoxic ac-
tivity against cancer cells) via IL-10 as an intermediate; (2) directly
inhibits anti-tumoral Th1-type responses (i.e., cell-mediated
immunity) and M1-type macrophages; (3) suppresses cytotoxic
CD8+ T-lymphocytes, natural killer (NK) lymphocytes and dendritic
cells functions; (4) generates CD4 + CD25+ T-regulatory cells (T-reg)
that suppress activity of other lymphocyte populations; (5) promotes
M2-type macrophages with pro-tumoral activities (Wojtowicz-Praga,2003; Teicher, 2007; Truty & Urrutia, 2007; Yang, 2010; Yang et al.,
2010; Achyut & Yang, 2011). This feature is of particular interest in tu-
mors expressing immunogenic antigens such as melanoma (Perrot
et al., 2013). TGFβ was shown to increase the expression of monocyte
chemoattractant protein-1 (MCP-1) and IL-10 in melanoma cells, en-
hancing tumor inﬁltration and immunosuppression (Diaz-Valdes
et al., 2011).
Solid tumors display a non-random metastatic tropism, suggest-
ing that cancer cells need to be adapted to distant site to engraft
and proliferate (Bhowmick, 2012). The microenvironment of both
the primary and the metastatic tumor sites can determine the ability
for a disseminated tumor to progress. For example, TGFβ signaling
contributes to colon cancer metastasis into the liver and lungs.
Calon et al. (Calon et al., 2012) demonstrated that constitutively
TGFβ-pathway inactive KM12L4a colorectal cancer cells (homozygote
TGFBRIImutation) were unable to develop metastasis in an orthotopic
xenograft mouse model, while KM12L4a engineered to secrete TGFβ
developed lung and/or liver metastasis without any autocrine activa-
tion of the TGFβ pathway in tumor cells. In addition, subcutaneous inoc-
ulation of patients’ puriﬁed colorectal cancer stem cells expressing
TGFβ in immunodeﬁcient mice generated tumors that ellicited a strong
TGFβ pathway activation in stromal cells at both primary and metasta-
tic sites.
Finally, the role of stromal neural cells as a promoter of tumor
growth and metastasis is receiving growing attention (Demir et al.,
2012). There is emerging data regarding the role of TGFβ signaling
in the interactions between nerve cells and cancer cells (Aigner &
Bogdahn, 2008; Haas et al., 2009). For example, TGFβ has been shown
to induce nerve growth factor expression in pancreatic stellate cells by
activation of the ALK-5 pathway (Haas et al., 2009).
To summarize, at the microenvironment level, the TGFβ pathway
mediates a broad spectrum of tumor-stroma interactions in both early
and late tumor stages, creating a favorable microenvironment for
tumor initiation, cancer cell growth and metastasis, and establishing a
key thread of pro-tumoral activities throughout the steps of carcinogen-
esis. This establishes interpendencies between the cancer cells that dis-
play altered or no response to TGFβ, and the TGFβ-stimulated and
responsive stromal cells. Thus, TGFβ targeted therapymay affect cancer
cells by indirect, microenvironment-mediated,mechanisms throughout
all the steps of carcinogenesis.3. TGFβ pathway inhibitors: preclinical and clinical results
3.1. Classiﬁcation of agents targeting the TGFβ pathway for cancer therapy
Many TGFβ pathway inhibitors have been investigated in the
preclinical setting, some of which are now in clinical development.
Schematically, TGFβ pathway inhibition can be realized at three levels:
(i) the ligand level: antisense oligonucleotides delivered directly intra-
venously or engineered into immune cells to prevent TGFβ synthesis
(for example, trabedersen [AP12009], an antisense oligonucleotide
targeting TGFβ2; and Lucanix® [belagenpumatucel-L], a TGFβ2 anti-
sense gene-modiﬁed allogeneic cancer cell vaccine); (ii) the ligand-
receptor level: ligand-traps (TGFβ-neutralizing monoclonal antibodies
and soluble receptors) and anti-TGFβ-receptor monoclonal antibodies
to prevent ligand-receptor interaction (for example, fresolimumab, a
pan-TGFβ antibody; disitertide [P144], a peptidic TGFβ1 inhibitor spe-
ciﬁcally designed to block the interaction with its receptor; and IMC-
TR1 [LY3022859], amonoclonal antibody against TGFβRII) ; and (iii) in-
tracellular level: TGFβ receptor kinase inhibitors to prevent signal
transduction (for example, galunisertib [LY2157299], a small molecule
inhibitor of TGFβRI, which is to date the most advanced TGFβ signaling
inhibitor under clinical development) (Smith et al., 2012; Katz et al.,
2013). Molecules under clinical development in oncology are summa-
rized in Table 1.
Table 1
TGFβ pathway inhibitors in development in cancer.
Name Targets Trial identiﬁer Current status
TGFβ ligand inhibitors
Lerdelimumab
(CAT-152)
Genzyme®
TGFβ2 Development stopped
Metelimumab
Genzyme®
TGFβ1 Development stopped
Fresolimumab (GC1008)
Genzyme®/Aventis®
TGFβ1, -β2, -β3 NCT00356460
NCT00923169
NCT01472731
NCT01112293
NCT01401062
Results in RCC, melanoma, mesothelioma and glioma;
combination phase I/II in progress in breast cancer
LY2382770
Eli Lilly®
TGFβ1 In progress outside oncology
Trabedersen
(AP12009)
Antisens Pharma®
TGFβ2 NCT00844064
NCT00431561
NCT00761280
Results in glioma, PDAC, CRC, melanoma and glioblastoma
Lucanix
(Belagenpumatucel-L)
NovaRx Corporation®
TGFβ2 NCT01058785
NCT00676507
Results in glioma and NSCLC; combination phase I in progress
FANG™ Vaccine
(rhGMCSF/shRNAfurin)
Gradalis®
TGFβ1, -β2 NCT01061840
NCT01309230
NCT01505166
NCT01453361
In progress in melanoma, CRC and ovarian cancer
Disitertide
(P144)
Digna Biotech®
TGFβ1 In progress outside oncology
TGFβ receptor inhibitors
Galunisertib
(LY2157299)
Eli Lilly®
TGFβRI NCT01246986
NCT01373164
NCT01220271
NCT02178358
NCT01582269
Phase II in progress in PDAC, HCC, glioma and glioblastoma
TEW-7197
MedPacto®
TGFβRI NCT02160106 Phase I in progress
PF-03446962
Pﬁzer®
ALK-1 (TGFβRI) NCT00557856
NCT01337050
NCT01911273
NCT01486368
NCT01620970
NCT02116894
Results of phase I; phase II results pending in HCC and in progress
in malignant pleural mesothelioma and refractory urothelial
carcinoma; combination phase I in progress with regorafenib in CRC
IMC-TR1
(LY3022859)
Eli Lilly®
TGFβRII NCT01646203 Phase I in progress
CRC: colorectal carcinoma; HCC: hepatocellular carcinoma; NSCLC: non-small cell lung carcinoma; PDAC: pancreatic ductal adenocarcinoma; RCC:rRenal cell carcinoma.
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3.2.1. Effect on cancer cells
TGFβ pathway inhibitors display limited anti-proliferative activity
in vitro despite efﬁcient blockade of both canonical and non-canonical
pathway. Indeed, for example, galunisertib displayed potent inhibition
of canonical (inhibition of phospho-SMAD2) and non-canonical
(MAPK or PI3K/AKT/mTOR) pathways in a variety of in vitro HCC cell
linesmodels, of epithelial andmesenchymal phenotypes and regardless
of TGFβ pathway protein expression (Dituri et al., 2013; Dzieran et al.,
2013; Serova et al., 2013). The effects of TGFβ and galunisertib on prolif-
eration were not correlated with signal inhibition and were dependent
on the cellular context as deﬁned by Coulouarn et al. (Coulouarn et al.,
2008; Dituri et al., 2013; Dzieran et al., 2013; Serova et al., 2013). In
the “late TGFβ signature” cell group (SK-HEP1, SK-Suni, SK-Sora, JHH6,
HLE, HLF, and FLC-4 cell lines), no effects on proliferationwere observed
with galunisertib with or without TGFβ, while In the “early TGFβ signa-
ture” cell group (HepG2, Hep3B, HuH7, and PLC/PRF/5 cell lines), cancer
cells were sensitive to TGFβ dependent growth inhibition and displayed
limited sensitivity to galunisertib (Dzieran et al., 2013; Serova et al.,
2013). Despite limited anti-proliferative activity in vitro, galunisertib
had potent anti-invasive activity (Dituri et al., 2013; Dzieran et al.,
2013; Serova et al., 2013). Moreover, galunisertib displayed anti-
proliferative activity in ex vivo models representing a morephysiological model, suggesting that the TGFβ inhibition can exert
anti-tumoral effects and that these effects are mediated by tumor mi-
croenvironment (Dituri et al., 2013; Serova et al., 2013).
Noticeably, the interdependencies between cell types and the
crosstalk between TGFβ and other signaling pathways may lead to un-
expected effects of TGFβ inhibition. For example, TGFβ inhibition by
various agents (LY2109761, SD-208, and trabedersen) reduced PDAC
cells invasion in vitro and metastasis in vivo (Gaspar et al., 2007; Melisi
et al., 2008; Schlingensiepen et al., 2011). However, Oyanagi et al.
(Oyanagi et al., 2014) reported that inhibition of TGFβ signaling by
galunisertib or SB431542 potentiated PDAC cell invasion into collagen
matrix in 3D co-culture with ﬁbroblasts. This was due to crosstalk be-
tween the TGFβ and the hepatocyte growth factor (HGF) pathway,
another major invasion-promoting factor in PDAC. TGFβ inhibition in-
creased the secretion of HGF by ﬁbroblasts by blocking the HGF-
suppressing activity of cancer cell-derived TGFβ. These results from a
simpliﬁed tumor-stroma model suggest that TGFβ signaling inhibitors
may promote tumor progression under some pathological conditions.
3.2.2. Effect on ﬁbrosis
PDAC displays themost prominent desmoplastic stromal reaction of
all epithelial tumors, often greater than the epithelial component of the
tumor itself (Neuzillet et al., 2014). Activated ﬁbroblastic pancreatic
stellate cells (PSC) are responsible for excess ECM production in PDAC,
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(Apte et al., 2004). Interestingly, a study in the Panc-1 orthotopic
PDAC model, showed that TGFβRI inhibition by SD-208 treatment
signiﬁcantly decreased tumor growth and was associated with reduced
ﬁbrosis in the tumor microenvironment (Medicherla et al., 2007).
The Gianelli group (Mazzocca et al., 2010) reported similar observa-
tion in a HCC xenograft mouse model. They showed that HCC cell lines
producing high levels of CTGF generated high stromogenic tumors,
which was reversed by CTGF knockdown. Upon TGFβ1 stimulation,
low-CTGF HCC cells formed tumors with a high stromal content and
CTGF expression, which was inhibited by treatment with LY2109761.
Blocking TGFβ signaling with LY2109761 or galunisertib inhibited
CTGF synthesis and release by HCC cells and reduced tumor stromal
content by inhibiting ﬁbroblastic cell proliferation (Mazzocca et al.,
2010).
3.2.3. Effect on angiogenesis
HCCs are typically hypervascularized tumors with predominant ar-
terial perfusion, and TGFβ plasma levels are positively correlated with
tumor vascularity (Ito et al., 1995). TGFβ stimulate HCC cancer cells to
produce VEGF. Mazzocca et al. (Mazzocca et al., 2009) demonstrated
that the TGFβRI inhibitor LY2109761 decreased microvessel density
(CD31 immunostaining) in a HCC xenograft model. Mechanistically,
LY2109761 blocked VEGF gene expression in HCC cells and paracrine
crosstalk with endothelial cells, and consequently the formation of tu-
moral blood vessels. This anti-angiogenic effect required functional
SMAD2/3 signaling in cancer cells. Interestingly, the anti-angiogenic
and anti-tumoral effects of LY2109761 were more potent than those
of bevacizumab, a speciﬁc anti-VEGF monoclonal antibody. Similarly,
reduced vessel density after treatment with TGFβ pathway inhibitor
was reported in colorectal cancer with SD-208 (Akbari et al., 2014),
and in glioblastoma models using LY2109761 (Zhang et al., 2011a,b).
The angiogenic effect of TGFβ1 in this latter model may be mediated
by JNK pathway and macrophage inﬁltration (Yang et al., 2013).
3.2.4. Effect on immune inﬁltration
Some tumors express immunogenic antigens but secrete a variety of
immunosuppressive cytokines, including TGFβ or IL-10, to outgrow and
evade host immune surveillance. The typical example of this immune
tolerance induction ismelanoma. This gave the rational for the develop-
ment of immunotherapy, aiming to reactivate the immune system
against these tumor antigens. TGFβ pathway inhibitors may contribute
to reverse this microenvironment-induced immune suppression, by
inhibiting T-reg and restoring natural killer and T cell-mediated cyto-
toxicity (Teicher, 2007). A large variety of TGFβ pathway inhibitors
(small molecules SB-431542, SD-108, SX-007, and SM-16; anti-TGFβ
antibodies; adenovirus expressing TGFβ1 or TGFβ2 shRNA; nanoscale
liposomal polymeric gels releasing TGFβ inhibitor; P144 and P17 syn-
thetic small peptides inhibiting TGFβ1 and TGFβ2) have been tested in
preclinicalmodels asmonotherapy or in combinationwith other immu-
notherapy (agonistic anti-TNFα receptor or anti-CD40 antibodies,
adenovirus expressing interferon (IFN)β, IL-2, anti-tumor vaccine) and
were shown to restore immune response and increase the efﬁcacy
of combined immunotherapy (Uhl et al., 2004; Tran et al., 2007;
Gil-Guerrero et al., 2008; Kim et al., 2008; Llopiz et al., 2009; Tanaka
et al., 2010; Wilson et al., 2011; Garrison et al., 2012; Park et al., 2012;
Oh et al., 2013; Xu et al., 2014). For example, in a model of advanced
melanoma, TGFβ down-regulation by means of a siRNA boosted the
vaccine efﬁcacy and inhibited tumor growth by52% comparedwith vac-
cine treatment alone, as a result of increased level of tumor inﬁltrating
CD8+ T cells and decreased level of T-reg (Xu et al., 2014). Similarly,
combination delivery of TGFβ inhibitor and IL-2 by nanoscale liposomal
polymeric gels signiﬁcantly delayed tumour growth, increased survival
of melanoma tumor-bearingmice, and increased the activity of NK cells
and of intratumoral-activated CD8+ T-cell inﬁltration (Park et al.,
2012).3.2.5. Effect on metastasis
ATGFβ-activatedmicroenvironment facilitates colon cancer cellme-
tastasis into the liver and lungs. Using an experimental model for liver
metastasis by splenic injection of colorectal CT26 cancer cells constitu-
tively expressing ﬁreﬂy luciferase in Balb/c mice, Zhang et al. (Zhang
et al., 2009) showed that LY2109761 signiﬁcantly reduced liver metas-
tases as monitored by bioluminescence imaging when compared with
vehicle control. The mean survival of LY2109761-treated mice was sig-
niﬁcantly prolonged (35.2 versus 24.5 days in control mice, p b 0.001).
The overall survival at 30 days was 85.71% in LY2109761-treated mice
and 0% in controlmice. Similarly, Calon et al. (Calon et al., 2012) demon-
strated that galunisertib reduced phospho-SMAD2 stromal positivity
and inhibited the formation of subcutaneous tumors by primary colo-
rectal cancer stem cells. The authors suggest that a TGFβ-stimulated
stromal cell response, involving IL-11, potentiates colon cancer engraft-
ment and growth at liver and lungmetastatic sites through activation of
the STAT3 pathway in cancer cells. This illustrates how targeting TGFβ
signaling can impact cancer cells by indirect mechanisms due to the in-
terdependencies with stromal cells, through the remodeling of primary
tumor and metastasis microenvironment.
The effects of TGFβ signaling at the microenvironment level are
summarized in Fig. 2.
3.3. Clinical results
Despite limited information on the microenvironmental effects of
TGFβ inhibitors in the published early phase clinical trials, some infor-
mation can be highlighted.
A series of phase I and II trials targeting TGFβ2 or TGFβ1/2 expres-
sion used a vaccine-based strategy (Belagenpumatucel-L and FANG vac-
cines), and thus aimed to restore immune response in the tumor
microenvironment. Belagenpumatucel-L, a TGFβ2 antisense gene-
modiﬁed non-viral based allogenic tumor cell vaccine, has been ex-
plored in a phase II trial in NSCLC at different stages (Nemunaitis et al.,
2006). Belagenpumatucel-L had an acceptable safety proﬁle and the
survival compared favorably with historical data, with a two-year over-
all survival (OS) rate of 47% in stage IIIB and stage IV patients who re-
ceived the higher doses of the vaccine. Authors showed that immune
activation may have contributed to a favorable clinical outcome.
Patients who achieved partial responses (PR) or stable diseases (SD)
were more likely to display elevated IFN-γ, IL-4, and IL-6 cytokine pro-
duction by peripheral blood mononuclear cells (PBMC), as well as anti-
HLA seroconversion to vaccine haplotypes. Based on previous positive
clinical data with GM-CSF-secreting allogeneic tumor cells, which activ-
ity may be impaired by TGFβ expression, the authors proposed to com-
bine the two approaches by creating a TAG vector co-expressing GM-
CSF and TGFβ2 antisense transgenes in an allogenic tumor cell vaccine
strategy (Olivares et al., 2011). Twenty-three patients with advanced
solid tumors received at least one vaccine injection in a phase I trial
(Olivares et al., 2011). The majority of patients experienced SD as their
best response and one patient had a prolonged complete response
(CR); the one-year OS rate was 35%. Similarly, patients with prolonged
SD or CR displayed a positive response to autologous TAG as shown by
the increased expression of IFN-γ in ELISPOT assay. As TGFβ1 and
TGFβ2 isoforms have redundant functions, a vector combining GM-
CSF gene expressionwith the expression of a bi-functional short hairpin
RNAi (bi-shRNAi) targeting the furin convertase, which is involved in
both TGFβ1 and TGFβ2 maturation, was developed. The resulting
FANG vaccine was evaluated in a phase I study with similar beneﬁts
than in the previous trials, i.e. FANGvaccine displayed a good safety pro-
ﬁle and was able to induce an immune response that was associated
with prolonged disease control (Senzer et al., 2012).
Fresolimumab, a human anti-TGFβ1/2/3 monoclonal antibody has
been tested in a phase I study involving mostly patients with advanced
melanoma (n = 28/29) (Morris et al., 2014). Fresolimumab was well
tolerated; six patients had prolonged SD and one patient achieved PR.
Fig. 2. Summary of the effects of TGFβ at the microenvironment level. bFGF: basic ﬁbroblast growth factor; CTGF: connective tissue growth factor; EMT epithelial-to-mesenchymal tran-
sition; IL-11: interleukin-11; VEGF: vascular endothelial growth factor. Fibrosis: TGFβmediates the dialogue between cancer cells and cancer-associated ﬁbroblastic cells (ﬁbroblasts and
stellate cells) by stimulating cancer cells to produce CTGF that has pro-ﬁbrotic effects. Angiogenesis: TGFβ has pro-angiogenic activity by cooperatingwith and upregulating the expression
of angiogenic factors (VEGF, bFGF, CTGF) by cancer cells, with direct or indirect effects on quiescence, migration, and proliferation of endothelial cells. Metastasis: TGFβ promotes metas-
tasis by enhancing EMTand cancer cellmotility and invasion. It also creates a favorablemicroenvironment for cancer cell engraftment and growth at liver and lungmetastatic sites through
modulation of cytokines such as IL-11. Immunity: TGFβ induces a pro-tumoral state of immune tolerance by deregulating the immune balance towards immunosuppression and inﬂam-
mation, with a predominant Th2 proﬁle.
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levels of TGFβ and VEGF, tumor levels of TGFβ and TGFβ receptors,
and PBMC phospho-SMAD) were analyzed, but none correlated with
tumor characteristics or clinical outcome; this may be due to the small
sample size.
TβM1, a human anti-TGFβ1monoclonal antibody, has been tested in
18patients in a phase I study (Cohn et al., 2014). It showed a good safety
proﬁle. Despite no valuable information on tumor response, a number
of potential biomarkers were investigated. At speciﬁc TβM1 doses,
VEGF and bFGF plasma levels tended to decrease. Gene expression pro-
ﬁling showed that TGFβ1 pathway was activated in cancer patients’
whole blood compared to normal patients. However, the short dosing
duration did not translate into signiﬁcant antitumor effects in the
small number of patients investigated in this study.
PF-03446962, a fully humanmonoclonal antibody against ALK1, has
been tested in a phase I study, and showed some activities that sug-
gested potential development in patients that failed anti VEGF/VEGFR
therapy (Goff et al., 2011). In a following phase II study as a single
agent in platimum pre-treated patients with urothelial tumors, PF-
03446962 was considered inactive and the trial was stop at the ﬁrst in-
terim analysis for futility (Necchi et al., 2014).
In a phase IIb trial two doses of trabedersen (10 μM and 80 μM), a
synthetic TGFβ2 antisens oligodeoxynucleotide, were compared tostandard chemotherapy (temozolomide or procarbazine/lomustine/
vincristine) in 145 patients with recurrent or refractory glioblastoma
multiforme or anaplastic astrocytoma (Bogdahn et al., 2011). It did not
show superiority of trabedersen in controlling tumor growth at six
months, which was the primary endpoint. However, delayed responses
were observed even after treatment discontinuation, and 10 μM
trabedersen tended to be superior to chemotherapy in term of two-
year survival rate (p = 0.10). Median OS for 10 μM trabedersen was
39.1 months compared with 35.2 months for 80 μM trabedersen and
21.7 months for chemotherapy (not signiﬁcant).
Preliminary results of the ﬁrst phase II study of galunisertib as
second-line treatment in HCC after sorafenib (NCT01246986) were
presented at the ILCA 2013 and ASCO GI 2014 meetings (Faivre et al.,
2013); 106 patients were randomized to receive galunisertib at 160 or
300 mg/day. Galunisertib safety proﬁle was suitable for patients with
Child-Pugh A/B7 HCC. Median time to progression was 12 weeks.
galunisertib treatment was associated with AFP responses in 24% of pa-
tients, reduction in TGFβ1 and soluble E-cadherin levels, and time to
tumor progression was increased in patients with AFP and TGFβ1 levels
reduction from baseline. Interestingly, for patients with AFP con-
centrations above 200 UI/mL, the difference in time to tumor progres-
sion (TTP) and overall survival (OS) between responders and non-
responders remained highly signiﬁcant, suggesting that the effects of
29C. Neuzillet et al. / Pharmacology & Therapeutics 147 (2015) 22–31galunisertib might be more pronounced in poor prognostic patients
with elevated AFP at baseline. Further analysis is expected to launch
phase III clinical trials.
Altogether, these results highlight that TGFβ inhibition may achieve
prolonged disease control and that response to TGFβ inhibitors may be
delayed, as it has long been observed with immunomodulatory agents.
Identiﬁcation of reliable predictive biomarkers to identify which
patients are the most likely to beneﬁciate from these treatments is a
critical issue.4. Summary and perspectives
TGFβ signaling inhibition is an emerging strategy for cancer therapy.
As most cancer cells display altered or non-functional TGFβ signaling,
TGFβ inhibitors have limited effects on these cells and exert their anti-
tumoral activity mainly by affecting TGFβ responsive cells (ﬁbroblastic,
endothelial, and immune cells) in the tumor microenvironment. TGFβ
signaling inﬂuences tumor microenvironment by promoting ﬁbrosis,
angiogenesis, andmetastasis, and suppressing immune-related host re-
sponse. TGFβ inhibition may be considered primarily to normalize
tumor microenvironment homeostasis by down-regulating stromal
stimulation resulting from excess TGFβ production by tumor and
tumor-related tissues, with an indirect impact on cancer cells and limit-
ed expected side effects on normal tissues. This mechanism of action
illustrates how the interdepencies between cancer and stromal cells
can provide new therapeutic targets.
There are many clinical challenges to developing TGFβ inhibitors,
notably timing of treatment and predictive biomarkers for patient selec-
tion, in order to deﬁne in what kind of tumor microenvironment TGFβ
inhibition may be more beneﬁcial. TGFβ inhibition may be of particular
interest in the early setting as a preventive strategy in tumors arising on
chronic inﬂammation and ﬁbrosis, in which TGFβ overproduction pre-
cedes tumor formation and create a favorable microenvironment for
cancer cells. This may be useful both in the primary prevention setting
and as adjuvant treatment after complete resection of tumor. Of note,
there may be a potential hazard of stimulating synchronous occult
tumors through the inhibition of TGFβ-induced tumor suppression
(particularly, with inhibitors of TGFβ receptors), depending on the pres-
ence of preneoplastic condition (e.g., chronic inﬂammation) and genetic
alteration background. However, clinical results of TGFβ inhibition in
the phase II study in HCC patients are reassuring, without evidence of
malignant transformation from underlying cirrhotic livers (Jakowlew,
2006; Faivre et al., 2013). Alternatively, TGFβ inhibition (i.e., by inhibi-
tors of TGFβ ligands) may be considered to down-regulate excess
TGFβ production that arises as a consequence of tumor development.
Thus, TGFβ inhibitors may be preferentially used in the advanced
setting.
As TGFβ inhibitors are mainly targeting the tumor microenviron-
ment, with little or dual effect on cancer cell proliferation, they should
be used in combination with cytotoxic agents to kill these latter cells.
In addition, radiotherapy and chemotherapy can induce TGFβ activity,
possibly promoting metastatic progression, and high levels of TGFβ
are associated with resistance to anticancer treatments (Biswas et al.,
2007; Drabsch & ten Dijke, 2012). Then, combined TGFβ inhibition
may enhance tumor sensitivity to chemotherapy and radiotherapy
(Drabsch & ten Dijke, 2012). There is also a rationale for combination
with other therapies targeting tumor microenvironment. For example,
TGFβ cooperates with hypoxia to induce EMT and VEGF signaling
through HIF-1α induction (Copple, 2010; Drabsch & ten Dijke, 2012;
Mimeault & Batra, 2013). This provides a rationale for the use of TGFβ
pathway inhibitors in combination with or after failure of anti-
angiogenic agents (tyrosine kinase inhibitors such as sunitinib or soraf-
enib, or antibodies such as bevacizumab), or hypoxia-inducing proce-
dures such as arterial embolization. We also described that
combination with immunotherapies may be an option through therestoration of the immune response by TGFβ inhibitors (Yang, 2010;
Drabsch & ten Dijke, 2012).
Identiﬁcation of reliable predictive biomarkers of response to TGFβ
inhibitors is also a critical issue. AFP, TGFβ1, and soluble E-cadherin
levels have been suggested to predict response in HCC (Faivre et al.,
2013). More so than cancer cell characteristics, predictive power of bio-
markers in terms of TGFβ inhibitor efﬁcacymay be related to the tumor
microenvironment or a patient’s overall blood biomarker proﬁle
(Neuzillet et al., 2014). For example, patients with high intra-tumoral
and/or circulating levels of TGFβmay be more likely to respond to spe-
ciﬁc TGFβ inhibitors.
In conclusion, microenvironment remodeling by TGFβ, in space and
time, generates a favorable microenvironment for tumor growth and
metastasis. TGFβ inhibitors have entered clinical development in cancer
patients with encouragingﬁrst clinical results. The future of TGFβ inhib-
itors in cancer therapy as tumor microenvironment targeting agents is
promising and opensnew challenges in terms of biomarkers and patient
selection.
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